Concepedia
Statistics
Publications
29
Citations
6.5K
H-Index
20
Active since
2012
Affiliations
The University of Texas MD Anderson Cancer Center(Current)
Moffitt Cancer Center
Dana-Farber Cancer Institute
Stanford University
Amgen (United States)
Allen Xue is an author at The University of Texas MD Anderson Cancer Center specializing in immunotherapy, medicine, and oncology.
Publications per year
2012–2024
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations
Medicine, Oncology, Pharmacology +12
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Molecular Therapy · 2017 · 619 citations · Full text
Medicine, Immunology, Oncology +17
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer, Robert Somerville, Tangying Lu et al. · Journal of Clinical Oncology · 2017 · 561 citations
Medicine, Hematology, Immunology +17
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik S.G. Stroes, David Colquhoun, David Sullivan et al. · Journal of the American College of Cardiology · 2014 · 527 citations · Full text
Pharmacy, Immunology, Pharmacotherapy +14
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L. Locke, John M. Rossi, Sattva S. Neelapu et al. · Blood Advances · 2020 · 455 citations · Full text
1–5 of 29